Adrenocortical carcinoma (ACC) is a highly malignant tumor with an incidence of 1 to 1.6 cases per million per year. It presents with metastatic disease in up to 40% of cases. In advanced or recurrent disease treatment options are limited, and therapies using agents such as mitotane, cisplatin and adriamycin effect a tumor response rate of less than 30%. Pheochromocytomas have emerged as an endocrine malignancy with few options but with promising targets and very interesting genetics and these are being pursued. In adrenocortical cancer we are pursuing genetic and expression analyses to better understand these unique cancers and their diverse biology. Pheochromocytomas present a very rare disease with very unique biological and clinical properties and with increasingly complex and puzzling genetics. We are pursuing clinical strategies that will hopefully lead to better therapies and better understanding of how our therapies work and preclinical and laboratory studies to better understand the biology of cancers driven by mutations in the SDHB gene.
|Veytsman, Irina; Nieman, Lynnette; Fojo, Tito (2009) Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 27:4619-29|
|Ghayee, Hans K; Havekes, Bas; Corssmit, Eleonora P M et al. (2009) Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocr Relat Cancer 16:291-9|
|Komlodi-Pasztor, E; Trostel, S; Sackett, D et al. (2009) Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells. Oncogene 28:3111-20|
|He, J; Makey, D; Fojo, T et al. (2009) Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine 36:189-93|
|Huang, Hui; Abraham, Jame; Hung, Elizabeth et al. (2008) Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020-8|
|Huang, Hui; Fojo, Tito (2008) Adjuvant mitotane for adrenocortical cancer--a recurring controversy. J Clin Endocrinol Metab 93:3730-2|